Loss of heterozygosis on chromosome 18q21-23 and muscle-invasive bladder cancer natural history

Cai,Tommaso; Mondaini,Nicola; Tiscione,Daniele; Dal Canto,Maurizio; Santi,Raffaella; Bartoletti,Riccardo; Nesi,Gabriella

doi:10.3892/ol.2015.3616

Loss of heterozygosis on chromosome 18q21-23 and muscle-invasive bladder cancer natural history

Authors:
- Tommaso Cai
- Nicola Mondaini
- Daniele Tiscione
- Maurizio Dal Canto
- Raffaella Santi
- Riccardo Bartoletti
- Gabriella Nesi
View Affiliations

Affiliations: Department of Urology, Santa Chiara Regional Hospital, Trento 38123, Italy, Department of Urology, University of Florence, Florence 50121, Italy, Department of Medical Genetics, University of Florence, Florence 50121, Italy, Department of Pathology and Oncology, University of Florence, Florence 50121, Italy
Published online on: August 17, 2015 https://doi.org/10.3892/ol.2015.3616
Pages: 2569-2573

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Loss of heterozygosis (LOH) on chromosome (Chr) 18q21-23 was reported to be one of the most common genetic alterations identified in bladder cancer. The current study aimed to determine the prognostic role of LOH on Chr 18q21-23 in patients diagnosed with muscle‑invasive urothelial bladder carcinoma (MIBC). A total of 34 consecutive patients were enrolled in the present prospective study. LOH on Chr 18 was assessed by performing multiplex polymerase chain reaction on paired blood and tumour tissue samples from each patient. The following primers were used in the present study: D18S51, MBP LW and MBP H. These data were then compared with follow‑up information. The main outcome measure was patient status at the end of the follow‑up. Cox regression was used to evaluate the impact of each parameter on cancer‑specific survival and the Kaplan Meier test for disease‑free survival was plotted in order to estimate survival. Out of 34 patients, 18 (52.9%) exhibited ≥1 alteration in one of the loci analysed on chromosome 18, while 16 (47.1%) revealed no alterations. No correlation was identified with stage (P=0.18) or grade (P=0.06); however, LOH on Chr 18q21‑23 was significantly associated with a lower recurrence‑free probability (P<0.0001). Kaplan‑Meier curves demonstrated a significant association between patient status at follow‑up and LOH on Chr 18 (P<0.001). In addition, multivariate analysis identified LOH on Chr 18 (P<0.001) and stage (P=0.01) as independent survival predictors. Furthermore, artificial neural network analysis was consistent with the results of the multivariate analysis. In conclusion, the present study highlighted the role of LOH on Chr 18q21-23 in predicting the clinical outcome of patients with MIBC.

View Figures

View References

1	Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66. 2007. View Article : Google Scholar : PubMed/NCBI
2	MhawechFauceglia P, Cheney RT and Schwaller J: Genetic alterations in urothelial bladder carcinoma: An updated review. Cancer. 106:1205–1216. 2006. View Article : Google Scholar : PubMed/NCBI
3	Tomasini JM and Konety BR: Urinary markers/cytology: What and when should a urologist use. Urol Clin North Am. 40:165–173. 2013. View Article : Google Scholar : PubMed/NCBI
4	Cai T, Nesi G, Dal Canto M, Mondaini N, Piazzini M and Bartoletti R: Prognostic role of loss of heterozygosity on chromosome 18 in patients with low-risk nonmuscle-invasive bladder cancer: Results from a prospective study. J Surg Res. 161:89–94. 2010. View Article : Google Scholar : PubMed/NCBI
5	Bartoletti R, Cai T, Nesi G, Roberta Girardi L, Baroni G and Dal Canto M: Loss of P16 expression and chromosome 9p21 LOH in predicting outcome of patients affected by superficial bladder cancer. J Surg Res. 143:422–427. 2007. View Article : Google Scholar : PubMed/NCBI
6	Bartoletti R, Cai T, Dal Canto M, Boddi V, Nesi G and Piazzini M: Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: A rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma. J Urol. 175:2032–2037. 2006. View Article : Google Scholar : PubMed/NCBI
7	Knowles MA: What we could do now: Molecular pathology of bladder cancer. Mol Pathol. 54:215–221. 2001. View Article : Google Scholar : PubMed/NCBI
8	Uchida A, Tachibana M, Miyakawa A, Nakamura K and Murai M: Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res. 28:297–303. 2000. View Article : Google Scholar : PubMed/NCBI
9	Switula D: Principles of good clinical practice (GCP) in clinical research. Sci Eng Ethics. 6:71–77. 2000. View Article : Google Scholar : PubMed/NCBI
10	Polymeropoulos MH, Xiao H and Merril CR: Tetranucleotide repeat polymorphism at the human myelin basic protein gene (MBP). Hum Mol Genet. 1:6581992. View Article : Google Scholar : PubMed/NCBI
11	Bartoletti R, Dal Canto M, Cai T, Piazzini M, Travaglini F, Gavazzi A and Rizzo M: Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment. Oncol Rep. 13:531–537. 2005.PubMed/NCBI
12	DalCanto M, Bartoletti R, Travaglini F, Piazzini M, Lodovichi G, Rizzo M and Selli C: Molecular urinary sediment analysis in patients with transitional cell bladder carcinoma. Anticancer Res. 23:5095–5100. 2003.PubMed/NCBI
13	Edge SB, Byrd DR, Compton CC, et al: American Joint Committee on Cancer Staging Manual. 7th. Springer; New York, NY: pp. 117–126. 2010
14	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press; Lyon, France: pp. 89–154. 2004
15	Gakis G, Efstathiou J, Lerner SP, et al: International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012: ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 63:45–57. 2013. View Article : Google Scholar : PubMed/NCBI
16	Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A and Witjes JA: European Association of Urology (EAU): Treatment of muscle-invasive and metastatic bladder cancer: Update of the EAU guidelines. Eur Urol. 59:1009–1018. 2011. View Article : Google Scholar : PubMed/NCBI
17	Cai T, Conti G, Lorenzini M and Bartoletti R: Artificial intelligences in urological practice: The key to success? Ann Oncol. 18:6042007. View Article : Google Scholar : PubMed/NCBI
18	Cai T, Conti G, Nesi G, et al: Artificial intelligence for predicting recurrence-free probability of noninvasive high-grade urothelial bladder cell carcinoma. Oncol Rep. 18:959–964. 2007.PubMed/NCBI
19	Lee SE and Park MS: Prognostic factors for survival in patients with transitional cell carcinoma of the bladder: Evaluation by histopathologic grade, pathologic stage and flow-cytometric analysis. Eur Urol. 29:193–198. 1996.PubMed/NCBI
20	GarciaClosas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina Olsson L, Wang Z, Lin J, et al: A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet. 20:4282–4289. 2011. View Article : Google Scholar : PubMed/NCBI
21	Koutros S, Baris D, Fischer A, et al: Differential urinary specific gravity as a molecular phenotype of the bladder cancer genetic association in the urea transporter gene, SLC14A1. Int J Cancer. 133:3008–3013. 2013.PubMed/NCBI
22	Brewster SF, Gingell JC, Browne S and Brown KW: Loss of heterozygosity on chromosome 18q is associated with muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 70:697–700. 1994. View Article : Google Scholar : PubMed/NCBI